Boston Scientific, a major medical device maker, has trimmed its full-year financial outlook after a cybersecurity incident disrupted its manufacturing and shipping operations. The company said the August 25 attack knocked roughly three percentage points off third-quarter sales growth and reduced adjusted earnings per share by $0.07. Shares fell as much as 9.9% in intraday trading as investors reacted to the lowered guidance.
What the new numbers look like
Boston Scientific now expects full-year adjusted earnings per share (EPS) of $3.16 to $3.18, down from its previous range of $3.28 to $3.32. It also sees net sales growth of about 4.25%, compared with the earlier forecast of 5.5% to 6.5%. Adjusted EPS is a common metric that excludes one-time items and is often used by investors to gauge a company's underlying profitability.
For the September quarter, the company reported adjusted EPS of $0.73, slightly above the $0.72 analysts had expected, on sales of $5.14 billion, up 1.5% from a year earlier. But the impact of the cyberattack is lingering. Boston Scientific expects December-quarter adjusted EPS of $0.77 to $0.79 and sales down 1% to 3% from the same period last year. Analysts had been looking for $0.83 and modest growth.
Why repeated guidance cuts matter
When a company revises its forecasts multiple times in a single year, investors start to question the reliability of its earnings. Truist Securities, an investment bank, noted that Boston Scientific has now forced three rounds of estimate cuts this year. That can change how the market values the stock.
Investors often apply a lower valuation multiple—essentially a lower price-to-earnings ratio—when a company's guidance keeps shifting. They demand a bigger cushion for uncertainty because reported earnings become less predictable. That's why a narrow beat, like the $0.73 versus $0.72 in the third quarter, may not provide much support if the next quarter's outlook is still being revised down and the cyber impact is still flowing through operations.
The concept of a "run-rate" is key here. It refers to the steady, repeatable earnings power of a business, assuming no one-off disruptions. Repeated forecast resets can make investors question whether the underlying run-rate is as strong as previously thought, even if the long-term product story remains intact.
What it means for investors
For everyday investors, this news is a reminder that cybersecurity incidents can have real financial consequences beyond just data breaches. They can disrupt production, delay shipments, and hit revenue and profits. In Boston Scientific's case, the impact is expected to continue into the final months of the year.
The company's shares are likely to stay under pressure until it can string together a few quarters of stable production, shipping, and guidance that stops shifting. Investors will be watching closely for signs that the operational disruption is fully resolved and that the company can return to its previous growth trajectory.
This story also highlights the broader risk that companies face from cyber threats. As businesses become more digital, a single attack can ripple through supply chains and financial results. For investors, it's worth considering how well a company is prepared to handle such disruptions, though that's often hard to assess from the outside.
Boston Scientific's situation is not unique. Other companies have faced similar challenges, and the market's reaction often depends on how quickly operations recover and whether guidance stabilizes. In this case, the repeated cuts suggest the recovery is taking longer than initially hoped.
For now, the key takeaway is that Boston Scientific's near-term earnings power has been dented, and the market is pricing in that uncertainty. The longer-term product story may still be intact, but investors are demanding a higher risk premium until the company proves it can deliver consistent results again.
